Evidence map›Paper›PMID 21931708›Full record

ArticlePloS one2011

Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.

Lili Chen, Zhengxiang He, Li Qin, Qinyan Li, Xibao Shi, Siting Zhao, Ling Chen, Nanshan Zhong, Xiaoping Chen

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02786589 phase1 / phase2unknown statusnot on this mapstarted 2016, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Non-small Cell Lung Cancer

TypeinterventionalSponsorState Key Laboratory of Respiratory DiseaseRan2016 to 2023Enrolled30ConditionsLung Cancer, Nonsmall CellArmsBlood-stage infection of P. vivax
NCT03375983 phase1 / phase2unknown statusnot on this mapstarted 2017, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Cancers

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2017 to 2026Enrolled20ConditionsAdvanced CancersArmsBlood-stage infection of P.vivax
NCT03474822 phase1 / phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Breast Cancers and Advanced Liver Cancers

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2018 to 2026Enrolled60ConditionsAdvanced Breast Cancer, Advanced Liver CancerArmsBlood-stage infection of P.vivax
NCT04165590 phase1 / phase2recruitingnot on this mapstarted 2019, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2019 to 2026Enrolled60ConditionsAdvanced Malignant Solid TumorArmsPlasmodium immunotherapy
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. The theory of tumor immuno-ecodynamics.Frontiers in immunology · 2026
    Article
  6. Article
  7. Review
  8. Frontiers in molecular biosciences · 2025
    Article
  9. Parasites revive hope for cancer therapy.European journal of medical research · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Parasites as potential targets for cancer immunotherapy.Journal of cancer research and clinical oncology · 2023
    Review
  17. Frontiers in oncology · 2023
    Article
  18. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023
    Review
  19. Review
  20. International journal of molecular sciences · 2022
    Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lili ChenCenter for Infection and Immunity, State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Zhengxiang He
Li Qin
Qinyan Li
Xibao Shi
Siting Zhao
Ling Chen
Nanshan Zhong
Xiaoping Chen
Chinese Academy of Sciences · CNState Key Laboratory of Respiratory Disease · CNGuangzhou Institutes of Biomedicine and Health · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is the most common malignancy in humans and its high fatality means that no effective treatment is available. Developing new therapeutic strategies for lung cancer is urgently needed. Malaria has been reported to stimulate host immune responses, which are believed to be efficacious for combating some clinical cancers. This study is aimed to provide evidence that malaria parasite infection is therapeutic for lung cancer. METHODOLOGY/PRINCIPAL

findingsAntitumor effect of malaria infection was examined in both subcutaneously and intravenously implanted murine Lewis lung cancer (LLC) model. The results showed that malaria infection inhibited LLC growth and metastasis and prolonged the survival of tumor-bearing mice. Histological analysis of tumors from mice infected with malaria revealed that angiogenesis was inhibited, which correlated with increased terminal deoxynucleotidyl transferase-mediated (TUNEL) staining and decreased Ki-67 expression in tumors. Through natural killer (NK) cell cytotoxicity activity, cytokine assays, enzyme-linked immunospot assay, lymphocyte proliferation, and flow cytometry, we demonstrated that malaria infection provided anti-tumor effects by inducing both a potent anti-tumor innate immune response, including the secretion of IFN-γ and TNF-α and the activation of NK cells as well as adaptive anti-tumor immunity with increasing tumor-specific T-cell proliferation and cytolytic activity of CD8(+) T cells. Notably, tumor-bearing mice infected with the parasite developed long-lasting and effective tumor-specific immunity. Consequently, we found that malaria parasite infection could enhance the immune response of lung cancer DNA vaccine pcDNA3.1-hMUC1 and the combination produced a synergistic antitumor effect. CONCLUSIONS/SIGNIFICANCE: Malaria infection significantly suppresses LLC growth via induction of innate and adaptive antitumor responses in a mouse model. These data suggest that the malaria parasite may provide a novel strategy or therapeutic vaccine vector for anti-lung cancer immune-based therapy.

Indexed as

Adaptive ImmunityAnimalsApoptosisCancer VaccinesCarcinoma, Lewis LungCell ProliferationCytokinesCytotoxicity, ImmunologicDendritic CellsDisease Models, AnimalImmunity, InnateKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMalariaMiceNeoplasm MetastasisCancer VaccinesCytokinesVaccines, DNA

Identifiers

PMID21931708
PMCPMC3170332
OpenAlexW2128066544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.